These findings challenge the view that GLUT3’s chemotherapeutic role is solely linked to glucose transport, suggesting a reevaluation of GLUT inhibitors’ use in tumor therapy, especially when combined with chemotherapeutic agents. The gene discussed is SLC2A1; the disease is neoplasm.